Vivozon Healthcare Appoints Lee Doohyun as Chairman and CEO of Vivozon
CEO Unification... Accelerating Merger with Vibozone Pharmaceutical
[Asia Economy Reporter Lee Gwan-ju] Vivoson Healthcare announced on the 6th that it has appointed Lee Doo-hyun, Chairman of Vivoson, as its CEO. Chairman Lee will now serve as CEO of Vivoson Healthcare, following his roles at Vivoson and Vivoson Pharmaceuticals.
Vivoson Healthcare joined the Vivoson Group in 2019. Recently, Voltia, where Chairman Lee is the largest shareholder, acquired a 30.52% stake in Vivoson Healthcare, resulting in a change of the largest shareholder.
The company explained that Lee was appointed CEO to facilitate a smooth merger with Vivoson Pharmaceuticals and to strengthen domestic clinical capabilities for Opiranserin, a non-opioid analgesic developed by Vivoson. This move is interpreted as a commitment to expedite the merger by unifying the CEO position.
Chairman Lee stated, "Internally, we are considering a merger and are working on integrating personnel across group companies and designing an efficient operational structure," adding, "As CEO of Vivoson Healthcare, I want to create a future where the Vivoson Group can grow together."
Hot Picks Today
"Koreans Spend 1 Million Won Each and Come Back"... 'They Said They Were Going for Value for Money,' but Open Their Wallets Wide in Japan- "You Mean Only Middle-Aged Men Got to Enjoy This?"... Where Japanese Women in Their 20s and 30s Are Flocking
- "Retired from Politics" Hong Joonpyo Defends Associates in Court for First Time in 25 Years: "I'm a Target... Had No Choice but to Step In"
- "Naked Again?" Controversial Actress Crosses a Line... Slammed for Sexualizing 'Child Characters'
- "They Get a Good Night's Sleep and Earn Twice My Salary... Honestly, I'm So Jealous I Could Die": Civil Servant's Post Targeting Firefighters Sparks Outrage
Chairman Lee is an expert in pain and neuroscience who has developed analgesics at several global pharmaceutical companies including Amgen, Johnson & Johnson, and Eli Lilly. He is currently leading Phase 3 clinical trials of Opiranserin in the US and domestically, and the second pipeline drug, the addiction treatment 'VVZ-2471,' has submitted an Investigational New Drug (IND) application for Phase 1 clinical trials in Korea.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
